Home > Drugs A – Z > Moxifloxacin (By mouth)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Moxifloxacin (By mouth)

This medicine is a quinolone antibiotic that treats infections.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Moxifloxacin is used to treat bacterial infections in many different parts of the body. Moxifloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. This medicine is available only with your doctor's prescription… Read more
Brand names include
Avelox
Other forms
Injection, Into the eye
Drug classes About this
Antibiotic

What works? Research summarized

Evidence reviews

Moxifloxacin versus levofloxacin for acute exacerbation of chronic obstructive pulmonary diseases: a systematic review

Bibliographic details: Wang XH, Liu XJ.  Moxifloxacin versus levofloxacin for acute exacerbation of chronic obstructive pulmonary diseases: a systematic review. Chinese Journal of Evidence-Based Medicine 2012; 12(6): 694-699 Available from: http://www.cjebm.org.cn/oa/DArticle.aspx?type=view&id=201206014

A meta analysis of the efficacy and safety of moxifloxacin in Chinese patients with multi-drug resistant pulmonary tuberculosis

Bibliographic details: Liu S, Chen S, Ren X, Zhang G.  A meta analysis of the efficacy and safety of moxifloxacin in Chinese patients with multi-drug resistant pulmonary tuberculosis. African Journal of Pharmacy and Pharmacology 2012; 6(1): 57-65 Available from: http://www.academicjournals.org/journal/AJPP/article-abstract/D50963D31352

Efficacy and safety of moxifloxacin for treating complicated intra-abdominal infections: a meta-analysis

Bibliographic details: Xi Q, Hu YF, Zheng XC.  Efficacy and safety of moxifloxacin for treating complicated intra-abdominal infections: a meta-analysis. Chinese Journal of New Drugs 2013; 22(2): 210-214 Available from: http://116.228.189.110/kns50/detail.aspx?dbname=CHKJ2013&filename=ZXYZ201302015&filetitle=%E8%8E%AB%E8%A5%BF%E6%B2%99%E6%98%9F%E6%B2%BB%E7%96%97%E5%A4%8D%E6%9D%82%E8%85%B9%E8%85%94%E6%84%9F%E6%9F%93%E7%9A%84%E7%96%97%E6%95%88%E5%92%8C%E5%AE%89%E5%85%A8%E6%80%A7%E7%9A%84Meta%E5%88%86%E6%9E%90

See all (26)

Summaries for consumers

Preventative antibiotic therapy for people with COPD

COPD is a common chronic respiratory disease mainly affecting people who smoke now or have done so previously. It could become the third leading cause of death worldwide by 2030. People with COPD experience gradually worsening shortness of breath and cough with sputum because of permanent damage to their airways and lungs. Those with COPD may have flare‐ups (or exacerbations) that usually occur after respiratory infections. Exacerbations may lead to further irreversible loss of lung function with days off work, hospital admission, reduction in quality of life and they may even cause death.

Substituting or adding fluoroquinolones to established first‐line antituberculous drug regimens gives no additional benefit or risks

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis bacteria. Over two billion people worldwide are believed to be latently infected with TB and approximately 10% of these people will develop active TB later in life. The World Health Organization currently only recommend treatment with fluoroquinolones for patients who cannot take standard first‐line drugs. In this review, we examined the effect of including fluoroquinolones in first‐line treatment regimens on people with presumed drug‐sensitive tuberculosis.

Antibiotic therapy for the treatment of methicillin‐resistant Staphylococcus aureus (MRSA)‐infected or colonised non surgical wounds

Non surgical wounds include chronic skin ulcers (such as pressure sores or diabetic ulcers), burns and traumatic wounds. Methicillin‐resistant Staphylococcus aureus (MRSA) can be present in 7% to 30% of such wounds, and the MRSA may spread into the bloodstream, causing a life‐threatening illness. A proportion of the wounds in which MRSA was present show signs of infection such as redness, pain, and pus discharge. The presence of MRSA without infection is called colonisation. It is not clear whether antibiotics should be used in MRSA colonised non‐surgical wounds. The antibiotic that has to be used in MRSA‐infected wounds is also not clear. We tried to find this out by performing a thorough search of the medical literature for studies that compared different antibiotic treatments for MRSA‐infected or MRSA‐colonised non surgical wounds. We included only randomised controlled trials, as, if they are conducted properly, they provide the best information. We included all relevant randomised controlled trials irrespective of the language in which the study was reported, the year of publication, and the number of people included in them. Two review authors independently identified the trials and extracted the relevant information in order to decrease the chance of an error occurring during this process.

PubMed Health Blog...

read all...